ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Sen. Grassley Presses Amgen on “Bundling.”

April 11, 2008

BRCA 1 Mutation Finding Draws Attention To Potential Perils Of Genetic Testing

October 6, 1995

In Brief: Simone, LoBuglio Lead AACI; AMA Honors B.J. Kennedy; FDA Meet Patient Advocates

July 31, 1992

1.7% Cut Expected in NCI Budget Under Deficit Agreement

November 24, 1989

In Brief: Masnyk Named DCBD Deputy Director Maizel to Head NCI’s “Supercomputer” Development

November 2, 1984

Edward Harlow Returns to NCI As Special Assistant to Varmus

January 14, 2011